Seqera

Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.

In order to cure diseases with unmet medical requirements, ARTHEx Biotech, a biotech business that was spun off from the University of Valencia in Spain, conducts research and develops innovative oligonucleotide treatments that control microRNA. In order to produce exploratory miR-modulating oligonucleotides that are intended to enter pertinent tissues in pharmacological quantities and treat disorders in which microRNAs play a significant role, ARTHEx has created its own technology, the ENTRY TM platform. ATX-01, an antimiR for Myotonic Dystrophy Type 1 that is in preclinical development, is the first experimental medicine from this technology (DM1) More than 900,000 people worldwide suffer from DM1, an orphan disease for which there is currently neither a cure nor an approved treatment.

Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.

Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company

Oryzon Genomics is a biopharmaceutical organization creating epigenetics-based therapeutics for patients with disease and CNS problems. Oryzon can distinguish and approve biomarkers and restorative focuses through its epigenetic stage and transform them into cutting edge and customized treatments. Oryzon Genomics has a developing portfolio, with two mixtures in Phase II clinical preliminaries: iadademstat (otherwise known as ORY-1001), a powerful and specific LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS enhanced LSD1 inhibitor for the treatment of neurological illnesses. The portfolio incorporates ORY-3001, a particular LSD1 inhibitor in preclinical improvement for the treatment of non-oncological illnesses.

Aortyx is an innovative company created by scientists from IQS School of Engineering and Hospital Clínic de Barcelona with the goal of developing advanced endovascular devices for treating vascular diseases. Our technology is designed to promote tissue regeneration by replicating the biomechanical properties of the aorta, creating an environment that supports cell movement and growth on a bioresorbable platform that closely resembles the natural dynamics of the aorta.

SpliceBio develops genetic medicines through its innovative Protein Splicing platform, focusing on gene therapies for genetic diseases. The company aims to address conditions caused by mutations in large genes, utilizing proprietary technologies to create novel treatment options. SpliceBio's pipeline includes programs targeting specific genetic disorders, such as Stargardt Disease. By leveraging its expertise in protein splicing, the company seeks to advance the field of gene therapy and improve patient outcomes. Through ongoing research and development, SpliceBio contributes to the understanding and treatment of complex genetic conditions.

The Company's corporate purpose is: I) the development of new high-value biotechnological solutions based on living microorganisms, bioactive molecules and new biomaterials. II) The manufacture and commercialization of: - optimized culture media for the industrial production of microorganisms; and. -probiotic and postbiotic products for various industrial sectors, including agriculture and aquaculture.

High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications. *FDA breakthrough Designation* Pioneering Precision Neurology

Overture Life is a biotechnology company that specializes in developing automated technologies for assisted reproductive procedures, with the goal of improving the efficiency and availability of in vitro fertilization (IVF). Their solutions focus on automating intricate processes in the embryology lab, such as egg freezing and embryo thawing, in order to enhance consistency and lower expenses. The company's DaVitri platform is designed to standardize these procedures, potentially leading to higher oocyte survival rates and reducing the necessity for multiple IVF cycles.